Compare INLF & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLF | PRFX |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.1M |
| IPO Year | 2023 | 2020 |
| Metric | INLF | PRFX |
|---|---|---|
| Price | $0.20 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.4M | 27.1K |
| Earning Date | 09-24-2026 | 09-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.58 |
| 52 Week High | $9.91 | $5.39 |
| Indicator | INLF | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 22.13 | 36.68 |
| Support Level | N/A | $0.69 |
| Resistance Level | $0.52 | $1.28 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 1.46 | 22.15 |
INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. Its portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.